NCT07592910: A Study of Mevrometostat With Enzalutamide in People With Prostate Cancer Who Have Previously Received Androgen Receptor Pathway Inhibitor Therapy
- State
- Not started
- Phase
- Phase 2
- People
- 60 planned
- Started
- Aug 2026
- Primary completion
- May 2029
- Arms
- Mevrometostat + Enzalutamide
- Results
- None posted
- 18 May 2026: Trial registered